Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADVMNASDAQ:ANEBNYSE:CLDINASDAQ:IRD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADVMAdverum Biotechnologies$2.51+3.3%$2.99$1.78▼$10.14$52.44M1.03268,169 shs338,959 shsANEBAnebulo Pharmaceuticals$1.08+2.1%$1.06$0.80▼$3.08$44.37M-1.1218,605 shs3,264 shsCLDICalidi Biotherapeutics$0.36+3.2%$0.45$0.34▼$3.89$11.35M1.21890,126 shs571,662 shsIRDOpus Genetics$1.01-7.3%$0.90$0.65▼$1.75$60.26M0.06483,732 shs1.67 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADVMAdverum Biotechnologies+9.95%+9.95%-30.37%-42.82%-69.32%ANEBAnebulo Pharmaceuticals+5.82%-5.52%-7.98%+0.78%-48.38%CLDICalidi Biotherapeutics-1.23%-15.69%-30.54%-57.52%+34,599,900.00%IRDOpus Genetics+8.64%+6.86%+14.21%+9.00%+108,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADVMAdverum Biotechnologies4.0387 of 5 stars3.41.00.04.82.72.50.6ANEBAnebulo Pharmaceuticals2.315 of 5 stars3.53.00.00.02.71.70.0CLDICalidi Biotherapeutics1.9005 of 5 stars3.53.00.00.00.01.70.6IRDOpus Genetics2.1726 of 5 stars3.50.00.00.02.70.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADVMAdverum Biotechnologies 2.80Moderate Buy$26.40951.79% UpsideANEBAnebulo Pharmaceuticals 3.00Buy$5.50409.26% UpsideCLDICalidi Biotherapeutics 3.00Buy$10.002,701.91% UpsideIRDOpus Genetics 3.00Buy$7.33626.07% UpsideCurrent Analyst Ratings BreakdownLatest CLDI, IRD, ADVM, and ANEB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025ADVMAdverum BiotechnologiesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$5.00 ➝ $4.005/15/2025ADVMAdverum BiotechnologiesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$33.00 ➝ $33.005/15/2025ADVMAdverum BiotechnologiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.005/15/2025ANEBAnebulo PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $3.004/17/2025ADVMAdverum BiotechnologiesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $33.004/16/2025ADVMAdverum BiotechnologiesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$10.00 ➝ $5.004/16/2025ADVMAdverum BiotechnologiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.004/11/2025IRDOpus GeneticsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.004/1/2025IRDOpus GeneticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$9.00 ➝ $8.004/1/2025IRDOpus GeneticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADVMAdverum Biotechnologies$1M52.44N/AN/A$8.26 per share0.30ANEBAnebulo PharmaceuticalsN/AN/AN/AN/A$0.15 per shareN/ACLDICalidi Biotherapeutics$50K226.94N/AN/A($2.32) per share-0.15IRDOpus Genetics$13.65M4.41N/AN/A$2.20 per share0.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADVMAdverum Biotechnologies-$117.17M-$6.40N/AN/AN/AN/A-65.14%-40.52%8/11/2025 (Estimated)ANEBAnebulo Pharmaceuticals-$8.20M-$0.26N/A∞N/AN/A-119.54%-108.08%N/ACLDICalidi Biotherapeutics-$29.22MN/A0.00N/AN/AN/AN/A-344.45%N/AIRDOpus Genetics-$9.99M-$2.10N/AN/AN/A-324.45%-63.65%-56.94%8/12/2025 (Estimated)Latest CLDI, IRD, ADVM, and ANEB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025IRDOpus Genetics-$0.34-$0.32+$0.02-$0.24$4.00 million$4.30 million5/13/2025Q3 2025ANEBAnebulo Pharmaceuticals-$0.05-$0.04+$0.01-$0.04N/AN/A4/15/2025Q4 2024ADVMAdverum Biotechnologies-$1.34-$1.96-$0.62-$1.96N/AN/A3/31/2025Q4 2024IRDOpus Genetics-$0.34-$1.27-$0.93-$1.27$11.10 million$3.40 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADVMAdverum BiotechnologiesN/AN/AN/AN/AN/AANEBAnebulo PharmaceuticalsN/AN/AN/AN/AN/ACLDICalidi BiotherapeuticsN/AN/AN/AN/AN/AIRDOpus GeneticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADVMAdverum BiotechnologiesN/A5.825.82ANEBAnebulo PharmaceuticalsN/A17.5117.51CLDICalidi BiotherapeuticsN/A0.190.19IRDOpus GeneticsN/A6.636.63Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADVMAdverum Biotechnologies48.17%ANEBAnebulo Pharmaceuticals28.40%CLDICalidi Biotherapeutics12.53%IRDOpus Genetics14.97%Insider OwnershipCompanyInsider OwnershipADVMAdverum Biotechnologies4.20%ANEBAnebulo Pharmaceuticals80.60%CLDICalidi Biotherapeutics24.28%IRDOpus Genetics6.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADVMAdverum Biotechnologies19020.89 million19.93 millionOptionableANEBAnebulo Pharmaceuticals441.09 million5.79 millionNot OptionableCLDICalidi Biotherapeutics3831.79 million20.04 millionN/AIRDOpus Genetics1459.66 million29.49 millionN/ACLDI, IRD, ADVM, and ANEB HeadlinesRecent News About These CompaniesIRD Opus Genetics, Inc.June 3 at 1:36 PM | seekingalpha.comOpus Genetics releases topline results from LYNX-2 evaluating phentolamine ophthalmic solution 0.75%June 2 at 4:58 PM | ophthalmologytimes.comOpus Genetics Shares Rise After Positive Trial Results for Eye TreatmentJune 2 at 4:58 PM | marketwatch.comOpus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast ConditionsJune 2 at 8:00 AM | globenewswire.comCritical Analysis: Opus Genetics (NASDAQ:IRD) and CannaPharmaRX (OTCMKTS:CPMD)May 24, 2025 | americanbankingnews.comOpus Genetics, Inc. (NASDAQ:IRD) Just Reported First-Quarter Earnings And Analysts Are Lifting Their EstimatesMay 18, 2025 | finance.yahoo.comOpus Genetics, Inc. (IRD) Reports Q1 Loss, Tops Revenue EstimatesMay 15, 2025 | zacks.comOpus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate UpdateMay 15, 2025 | globenewswire.comOpus Genetics to Present Advances in Gene Therapy for Inherited Retinal Diseases at Major Scientific Conferences in May 2025May 13, 2025 | nasdaq.comOpus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in MayMay 12, 2025 | globenewswire.comRMAT designation for Opus’ OPGx-LCA5 gene therapy candidateMay 7, 2025 | thepharmaletter.comOpus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy CandidateMay 6, 2025 | globenewswire.comOpus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful VisionMay 5, 2025 | globenewswire.comOpus Genetics shareholders approve key proposalsMay 3, 2025 | investing.comEarnings Preview: Opus Genetics, Inc. (IRD) Q1 Earnings Expected to DeclineMay 2, 2025 | zacks.comPRISM MarketView Spotlights Opus Genetics in New Q&A with CEO George MagrathApril 15, 2025 | markets.businessinsider.comCraig-Hallum Initiates Coverage of Opus Genetics (IRD) with Buy RecommendationApril 12, 2025 | msn.comCraig-Hallum bullish on Opus Genetics, initiates with a BuyApril 11, 2025 | markets.businessinsider.comOpus Genetics initiated with a Buy at Craig-HallumApril 11, 2025 | markets.businessinsider.comFounder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance ConcernsApril 11, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingNavitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBy Leo Miller | May 27, 2025View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookCanada Goose Soars 30%—Is This Rally Built to Last?By Thomas Hughes | May 21, 2025View Canada Goose Soars 30%—Is This Rally Built to Last?CLDI, IRD, ADVM, and ANEB Company DescriptionsAdverum Biotechnologies NASDAQ:ADVM$2.51 +0.08 (+3.29%) Closing price 04:00 PM EasternExtended Trading$2.51 0.00 (0.00%) As of 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.Anebulo Pharmaceuticals NASDAQ:ANEB$1.08 +0.02 (+2.06%) Closing price 04:00 PM EasternExtended Trading$1.10 +0.01 (+1.39%) As of 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.Calidi Biotherapeutics NYSE:CLDI$0.36 +0.01 (+3.15%) Closing price 04:00 PM EasternExtended Trading$0.36 0.00 (-0.53%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.Opus Genetics NASDAQ:IRD$1.01 -0.08 (-7.34%) Closing price 04:00 PM EasternExtended Trading$0.97 -0.04 (-4.36%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Reasons Amazon Could Be the Best Tech Performer in June Ollie’s Q1 Earnings: The Good, the Bad, and What’s Next Applied Digital: CoreWeave’s AI Deal Lights a $7 Billion Fuse Qualcomm: A Technical Deep-Dive Confirms the Worst Rocket Lab Expands Into Payloads: Should You Be Paying Attention? Steel Dynamics Shares Climb After Tariff Announcement Palantir Soars on Government Deals as Valuation Debate Lingers Broadcom Earnings Preview: AVGO Stock Near Record Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
